Evidence map›Paper›PMID 25083299›Full record

ArticleJournal of gastrointestinal oncology2014

KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas.

Yasemin Baskin, Yusuf Kagan Dagdeviren, Gizem Calibasi, Aras Emre Canda, Sulen Sarioglu, Hulya Ellidokuz, Ilhan Oztop

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yasemin Baskin1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Yusuf Kagan Dagdeviren1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Gizem Calibasi1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Aras Emre Canda1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Sulen Sarioglu1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Hulya Ellidokuz1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Ilhan Oztop1 Department of Basic Oncology, Institute of Oncology, 2 Department of Medical Informatics and Biostatistics, Faculty of Medicine, 3 Department of Surgery, Faculty of Medicine, 4 Department of Pathology, Faculty of Medicine, 5 Department of Preventive Oncology, Institute of Oncology, 6 Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer has a heterogeneous nature that is influenced by the tumour site. Many improvements have been made in identifying and characterizing the genetic alterations between colon and rectal cancers. However, there is not enough information about KRAS mutational differences between rectosigmoid and colon cancers arising elsewhere in the large bowel. The aim of this study was to determine the differences in the frequency of KRAS genetic alterations between rectosigmoid cancers and colon cancers.

methodsEighty-four patients diagnosed with colorectal cancer were included in this study. Genomic DNA was extracted from formalin-fixed paraffin-embedded tumour tissue sections. KRAS mutation analysis which was designed to detect the seven most common KRAS gene mutations (Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp) was performed. Chi-square test was used to test the association between mutation status and other variables.

resultsThis study represents the first KRAS mutational results from Turkish rectosigmoid cancer patients. The KRAS mutation frequency of rectosigmoid tumours is higher (34.3%, 12/35) than that of colon-localized tumours (30.6%, 15/49). However, there is no significant correlation between the KRAS mutation status and tumour location (rectosigmoid and colon).

conclusionsKRAS mutation analysis has a predictive and prognostic value in identifying tumours that may be resistant to treatment. Our study shows that differences in the biological behaviour of rectosigmoid and colon cancers should be considered. This finding highlights the importance of personalized cancer management, which could be assisted by cancer genotyping tools.

Indexed as

colon cancerKRAS mutationsRectosigmoid cancer

Identifiers

PMID25083299
PMCPMC4110495
OpenAlexW2177192818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.